The number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indirectly with replicative capacity and reduced drug susceptibility

AIDS Research and Human Retroviruses

Volumn 24, Issue 4, 2008, Pages 617-620

  Ross, L ^a   Parkin, N ^b   Lanier, R ^a  

^a GLAXOSMITHKLINE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL THERAPY; ARTICLE; DRUG RESISTANCE; DRUG SENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION RATE; PRIORITY JOURNAL; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; MUTATION; PHYSIOLOGY; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; UNITED STATES; VIRUS REPLICATION;

EID: 42449122705     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0188     Document Type: Article

References (10)

1. http: and aidsinfo.nih.gov/guidelines/. Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - May 4, 2006. 2007.
2. Petropoulos CJ, Parkin NT, Limoli KL, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
3. Delaugerre C, Roudiere L, Peytavin G, et al.: Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol 2005;32:241-244.
4. Ross L, Gerondelis P, Liao Q, et al.: Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naïve subjects treated with tenfovir/abacavir/lamivudine. Antiviral Ther 2005;10[S]:102.
5. Weber J, Chakraborty B, Weberova J, et al.: Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 2005;43:1395-1400.
6. Sharma PL and Crumpacker CS: Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997;71:8846-8851.
7. Frankel FA, Invernizzi CF, Oliveira M, et al.: Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 2007;21:665-675.
8. Pao D, Andrady U, Clarke J, et al.: Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004;37:1570-1573.
9. Barbour JD, Hecht FM, Wrin T, Liegler, et al.: Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004;18:1683-1689.
10. Persaud D, Palumbo P, Ziemniak C, et al.: Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007;195:1402-1410.